Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 8/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.46 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15592424 | 0.91 | SLC6A11 (0.45) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL764125 | 0.86 | SLC6A11 (0.52) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL28349162 | 0.83 | SLC6A11 (0.44) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL19463053 | 0.81 | SLC6A11 (0.42) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| Lithium Ion SCHEMBL19463707 | 0.81 | SLC6A11 (0.42) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL3088920 | 0.80 | SLC6A11 (0.48) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL29329320 | 0.80 | SLC6A11 (0.41) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL9908646 | 0.79 | SLC6A11 (0.47) | SLC6A11SLC6A1SLC6A12MEN1TP53 | |
| SCHEMBL8662709 | 0.77 | MTNR1B (0.37) | SLC6A11SLC6A1MEN1TP53KMT2A | |
| SCHEMBL16248722 | 0.76 | SLC6A11 (0.44) | SLC6A11SLC6A1SLC6A12MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179496-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250099594-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240245784-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-07-25 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-11896672-B2 | Targeted nucleic acid conjugate compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-13 | — | — | US | disclosed |
| US-20230110295-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-04-13 | — | — | US | disclosed |
| US-11427823-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-08-30 | — | — | US | disclosed |
| EP-3950004-A1 | TARGETED COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2022-02-09 | — | — | EP | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
| EP-3873530-A1 | THERAPEUTIC METHODS | Genevant Sciences GmbH (CH) | 2021-09-08 | — | — | EP | disclosed |
| CN-113365662-A | Method of treatment | 盖纳万科学有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20200407724-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-12-31 | — | — | US | disclosed |
| CN-110741087-A | Targeted compositions | 阿布特斯生物制药公司 | 2020-01-31 | — | — | CN | disclosed |
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-05-30 | — | — | US | disclosed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | disclosed |
| EP-3443092-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | SLC6A11 4380/4885SLC6A1 4300/4885SLC6A12 4230/4885 |
| US-20250099594-A1 | TARGETED COMPOSITIONS | HAVCR2, HDGF, NR1H4 | SLC6A11 4644/4885SLC6A1 4587/4885SLC6A12 4571/4885 |
| US-11896672-B2 | Targeted nucleic acid conjugate compositions | HAVCR2, DCTD, POLRMT | SLC6A11 4380/4885SLC6A1 4300/4885SLC6A12 4230/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | SLC6A11 4126/4885SLC6A1 3934/4885SLC6A12 4295/4885 |
| US-20240245784-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | SLC6A11 4380/4885SLC6A1 4300/4885SLC6A12 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.